Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.54 |
| ▸ | CTSK | P43235 | 8/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544394 | 1.00 | CTSS (0.54) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL5019146 | 1.00 | CTSS (0.54) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL22637154 | 0.90 | CTSS (0.50) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL606453 | 0.90 | CTSS (0.50) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL8296164 | 0.90 | CTSS (0.50) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL29398196 | 0.90 | MEN1 (0.49) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL6936247 | 0.90 | MEN1 (0.49) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL23979014 | 0.88 | CTSK (0.49) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL29157629 | 0.88 | CTSK (0.49) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL24130788 | 0.88 | CTSS (0.65) | CTSSCTSKCTSLCTSBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025108986-A1 | 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2025-05-30 | — | — | WO | disclosed |
| CN-119431181-A | Di-ene linker, linker-drug conjugate, antibody-conjugated drug and uses thereof | 泰诚思(上海)生物医药有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025031305-A1 | DIALLENE LINKER, LINKER-DRUG CONJUGATE, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | 泰诚思(上海)生物医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-12098147-B2 | Compound having novel structure, complex comprising same, anti-cancer pharmaceutical composition, and anti-cancer drug | ETNOVA THERAPEUTICS CORP. (KR) | 2024-09-24 | — | — | US | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| EP-0722442-B1 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR INC (US) | 2003-01-15 | — | — | EP | disclosed |
| US-5972307-A | ADMINISTERING TO HUMAN OR ANIMAL BODY AN EFFECTIVE AMOUNT OF A DIAGNOSTIC AGENT COMPRISES A METAL CHELATE OF A COMPOUND HAVING TWO MACROCYCLIC CHELANT GROUPS LINKED BY A BRIDGE CONTAINING ESTER OR AMIDE BOND | NYCOMED SALUTAR, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5650133-A | CHELATING AGENTS USEFUL IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS | NYCOMED SALUTAR (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0355041-B1 | Complex porphyrine compounds substituted in position 13,17 by propionic acid and propionic-acid derivatives, process for their preparation and pharmaceutical compositions containing same | SCHERING AG (DE) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009848-A2 | POLYAZACYCLOALKANES AS DICHELANTS | NYCOMED SALUTAR, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-5275801-A | X-ray and magnetic resonance imaging of tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0355041-A2 | Complex porphyrine compounds substituted in position 13,17 by propionic acid and propionic-acid derivatives, process for their preparation and pharmaceutical compositions containing same | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-02-21 | — | — | EP | disclosed |
| US-4410688-A | POLYAMIDES FROM DIAMINOCARBOXYLIC ACIDS | ALLIED CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | CTSS 4259/4885CTSK 4562/4885CTSL 4384/4885 |
| US-12098147-B2 | Compound having novel structure, complex comprising same, anti-cancer pharmaceutical composition, and anti-cancer drug | TP53, TOP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CTSS 2531/4885CTSK 2389/4885CTSL 3632/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | CTSS 3279/4885CTSK 2476/4885CTSL 1433/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | CTSS 3279/4885CTSK 2476/4885CTSL 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.